Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-03

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the research is to characterize the effect of labetalol, atenolol, and nifedipine on maternal hemodynamics early in pregnancy. Patients will be given medication based on their hemodynamics and asked to return for a repeat measurement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Elevated Blood Pressures in Early Pregnancy

NCT05955040

Elevated Blood Pressure Pregnancy Induced Hypertension

TERMINATED PHASE2

Impedance Cardiography to Decrease the Risk of Preeclampsia

NCT03245970

Chronic Hypertension Complicating Pregnancy (Diagnosis) Preeclampsia

WITHDRAWN EARLY_PHASE1

Response to Anti-hypertensives in Pregnant and Postpartum Patients

NCT03506724

Hypertension in Pregnancy Preeclampsia

COMPLETED PHASE4

Changes in Central Arterial Pressure When Comparing Nifedipine/Labetalol for Routine Hypertension Control in Pregnancy

NCT02912910

Hypertension

WITHDRAWN

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

NCT04790279

Hypertension in Pregnancy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

When a patient presents to the Maternal Hypertension Center at Cabell Huntington Hospital, she will receive a non-invasive hemodynamic assessment via the NICaS system as per usual protocol. The NICaS system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. In typical practice, the vasodilator nifedipine is initiated for increased systemic vascular resistance and elevated cardiac output is treated with beta blockade (via either atenolol or labetalol). The medication to be given to each subject will be based on their hemodynamics. Specifically, nifedipine will be given for a mean arterial pressure \>100 and a beta blocker will be given for a cardiac output \>8 l/min. The patients will be asked to return in one week for repeat ICG measurement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systolic Hypertension Pregnancy Related Diastolic Hypertension Cardiac Output, Low Cardiac Output, High

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beta blockade

Beta blocker (labetalol or atenolol) will be given for a cardiac output \>8 l/min.

Labetalol

Intervention Type DRUG

Beta blocker

Atenolol

Intervention Type DRUG

Beta blocker

Nifedipine

Nifedipine will be given for a mean arterial pressure \>100.

Nifedipine

Intervention Type DRUG

Calcium channel blocker

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Labetalol

Beta blocker

Intervention Type DRUG

Atenolol

Beta blocker

Intervention Type DRUG

Nifedipine

Calcium channel blocker

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Normodyne Trandate Tenormin Adalat CC Afeditab CR Nifediac CC Nifedical XL Procardia Procardia XL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presenting to Maternal Hypertension Center at Cabell Huntington Hospital
* English speaking
* 18-45 years old.
* Willing to provide informed consent
* Gestational age prior to 15 weeks gestation